Sponsor Overview
Explore verified public information about Servier's expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 3 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
Official Statements
Score contribution: 100 — 3 supporting sources.
“At Servier, such mechanisms are collectively referred as “Managed Access Programs” (MAPs). MAP covers different terms including “Compassionate Use”, “Early Access Authorization”, “Expanded Access”, “Named Patient Program”, “Named Patient Basis”, “Special Access Schemes/Programs” and others depending on local regulations.”
“Servier entity responsible for the operation of the medicinal product with early or compassionate access authorisation | . . Early access and compassionate access | Identification data Health data Personal life data Data relating to quality of life, conditions of use, efficacy and safety of the medicine ： Data collected from the patient's environment, which may be affected by the medicine taken In addition, provided that they are strictly necessary for the product prescribed | Legal obligation Another legal basis may apply depending on the country in which Servier entity is located.”
“Servier entity responsible for the operation of the medicinal product with early or compassionate access authorisation | Early access and compassionate access | ·Data relating to healthcare professionals involved in patient monitoring (in particular prescribing doctors and dispensing pharmacists) and staff acting under their responsibility or authority: name, first name, speciality, registration number in the shared directory of healthcare professionals (RPPS) and | Legal obligation Another legal basis may apply depending on the country in which the Servier entity is located.”
Past EAPs on ClinicalTrials.gov
Score contribution: 40 — 1 supporting sources.
Conditions: Glioma, Recurrence, Disease Attributes, Pathologic Processes, Neoplasms, Neuroepithelial, Neuroectodermal Tumors, Neoplasms, Germ Cell and Embryonal, Neoplasms by Histologic Type, Neoplasms, Neoplasms, Glandular and Epithelial, Neoplasms, Nerve Tissue
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.